In response to AbbVie's (ABBV.US) recent lawsuit against Baijinshu (06160.HK) for stealing trade secrets from its BTK degrader (BTK degrader), Interface News reported, Baijinshu denies the allegations and will resolutely defend its intellectual property rights against AbbVie in the lawsuit. The prosecution has launched a strong defense and is currently reviewing AbbVie's complaint carefully and will respond appropriately through legal process.

The case involved two products in development — AbbVie's BTK degradation agent ABBV-101 and Baizhin's BGB-16673; in addition, the case also involved Baijinzhou Executive Director Liu Huaqing, who was described as “a key figure in the theft of commercial secrets” before joining Baijinzhou. Work at AbbVie.

Baijinshu considers that the lawsuit is intended to impede the development of BGB-16673. The company filed for BGB-16673 for BGB-16673 years before AbbVie first filed for a patent on the BTK degradation agent. Baijinshu believes that its R&D projects comply with the principles of integrity. According to clinicaltrials.gov, the project was launched several years earlier than the AbbVie project, and the BGB-16673 development of the BGB-16673 development will not be interrupted by the lawsuit.

Among the two investigational drugs involved, BGB-16673 from Baijinshu is an oral, embedded-synergistic deactivation compound (CDAC) targeting Bruton tyrosine kinase (BTK) and the fastest progressing BTK degradation agent in the Baijinshu pipeline.